Microbot Medical (MBOT) Projected to Post Earnings on Wednesday

Key Points

• Microbot Medical is set to release its earnings data on August 13th, with analysts predicting an earnings per share (EPS) of ($0.08) for the quarter.
• In the last earnings report on May 21st, the company reported an EPS of ($0.08), exceeding the consensus estimate.
• The stock has seen recent institutional investment, with Goldman Sachs purchasing 37,744 shares in the first quarter, representing approximately 0.11% ownership of the company.

Microbot Medical (NASDAQ:MBOT - Get Free Report) is anticipated to release its earnings data before the market opens on Wednesday, August 13th. Analysts expect Microbot Medical to post earnings of ($0.08) per share for the quarter.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last announced its quarterly earnings results on Wednesday, May 21st. The biotechnology company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.07. On average, analysts expect Microbot Medical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Microbot Medical Stock Up 5.8%

MBOT stock traded up $0.17 during mid-day trading on Friday, hitting $3.09. The company had a trading volume of 1,929,972 shares, compared to its average volume of 2,236,193. The company has a market capitalization of $112.41 million, a price-to-earnings ratio of -4.75 and a beta of 1.15. Microbot Medical has a 12-month low of $0.82 and a 12-month high of $3.38. The company has a 50-day moving average price of $2.59 and a 200 day moving average price of $2.21.

Institutional Trading of Microbot Medical

A hedge fund recently raised its stake in Microbot Medical stock. Geode Capital Management LLC lifted its holdings in Microbot Medical Inc. (NASDAQ:MBOT - Free Report) by 24.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 395,039 shares of the biotechnology company's stock after buying an additional 78,121 shares during the period. Geode Capital Management LLC owned about 1.09% of Microbot Medical worth $996,000 at the end of the most recent reporting period. 16.30% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Microbot Medical from a "sell" rating to a "hold" rating in a research note on Saturday, June 14th.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.